NICE has now issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus.
This document together with the guidance published on autologous pancreatic islet cell transplantation for improved glycaemic control after pancreatectomy (IPG274) replaces previous guidance IPG13 on pancreatic islet cell transplantation.
Type 1 diabetes mellitus is a condition that occurs when the body does not produce enough insulin (a substance that helps control sugar balance in the body). It is usually treatable with insulin injections, but people with type 1 diabetes mellitus have an increased risk of other health problems, such heart disease. Allogeneic pancreatic islet cell transplantation involves the removal of cells called islet cells, which are responsible for the production of insulin, from human donors. These cells are inserted into the patient's liver to restart insulin production within the body. However, patients who have this procedure will need to take medications to help their bodies' immune system to accept the cells.
J54.4 Transplantation of islet of Langerhans
Y27.2 Allograft to organ NOC
Y53. - Approach to organ under image control
Note: Codes within category Y53.- are used as secondary codes to classify interventions that are percutaneous and require some form of image control: if the method of image control is unspecified, Y53.9 Unspecified approach to organ under image control is assigned.